Geocillin (carbenicillin indanyl sodium) is indicated in the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria. Geocillin is also indicated in the treatment of prostatitis due to susceptible strains of the following organisms: Escherichia coli Enterococcus (S. faecalis) Proteus mirabilis Enterobacter sp. Geocillin is acid stable, and rapidly absorbed from the small intestine following oral administration. It provides relatively low plasma concentrations of antibiotic and is primarily excreted in the urine. The antibacterial activity of Geocillin is due to its rapid conversion to carbenicillin by hydrolysis after absorption. Carbenicillin binds to penicillin-binding protein from corresponding bacteria. In April 2008, Pfizer has decided to discontinue the manufacturing of Geocillin (carbenicillin indanyl sodium). There are no other currently FDA approved manufacturers for carbenicillin tablets.